Sanofi may seek U.S. approval for Dengvaxia despite Philippines outrage

French pharmaceuticals group Sanofisays it will decide shortly whether to seek regulatory approval for dengue vaccine Dengvaxia in the United States, saying it was committed to the medicine despite a health scare in the Philippines.David Loew, the head of Sanofi Pasteur, the group's vaccines division, said the company had complied with all regulations and had no regrets about the vaccine, Dengvaxia, was developed despite the Philippines suspending a vast government immunisation programme because